NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

For immediate release

14 November 2023

Ergomed plc

Cancellation of admission to trading of Ergomed Shares

Further to the announcement on 13 November 2023 that the Scheme for the acquisition of the entire issued and to be issued ordinary share capital of Ergomed plc ("Ergomed" or the "Company") by Eden AcquisitionCo Limited has now become Effective in accordance with its terms, Ergomed confirms that AIM has cancelled the admission to trading of Ergomed Shares on AIM with effect from 7.00 a.m. today, 14 November 2023.

Defined terms used but not defined in this announcement have the meanings set out in the Scheme Document dated 22 September 2023.  All references to times in this announcement are to London time.

Enquiries:

Ergomed                                                                                                           +44 (0) 1483 307 920

Miroslav Reljanović (Executive Chairman)                                              

Jonathan Curtain (Chief Financial Officer)

Keith Byrne (Senior Vice President, Capital Markets and Strategy)